Japan first in the world to approve dupixent® (dupilumab) for chronic spontaneous urticaria (csu)

Approval based on results from phase 3 trial showing dupixent significantly reduced itch compared to placebo csu is the fifth approved indication for dupixent in japan and the sixth indication for dupixent globally tarrytown, n.y. and paris, feb. 16, 2024 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced that the ministry of health, labor and welfare (mhlw) in japan has granted marketing and manufacturing authorization for dupixent® (dupilumab) for the treatment of chronic spontaneous urticaria (csu) in people aged 12 years and older whose disease is not adequately controlled with existing therapy.
REGN Ratings Summary
REGN Quant Ranking